IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (Nasdaq: ALNY) concerning possible violations of federal securities laws.
If you purchased shares of Alnylam and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
The investigation concerns whether Alnylam and certain of its officers and/or directors violated federal securities laws. On October 5, 2016, Alnylam announced that it would discontinue development of revusiran (an investigational RNA interference therapeutic for the treatment of hereditary ATTR amyloidosis with cardiomyopathy) due to patient safety concerns. The Company stated that reports indicated patients taking revusiran in midstage trials had new or worsening complications of the disease.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some jurisdictions.
